STING1 and sarcoma: As poorly inflamed sarcomas are recalcitrant to immune-based therapies such as immune checkpoint inhibitors (14, 17–19, 21), we hypothesized that i.t. STING therapy would be an effective strategy to dismantle the immune suppressive sarcoma microenvironment and sensitize murine STSs to ICI.